Monopar Therapeutics Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Chandler D. Robinson
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1000 Skokie Boulevard Wilmette IL United States of America 60091
- IPO Date
- Dec 19, 2019
- CIK
- 0001645469
- Website
- monopartx.com
- Similar Companies
- Business
- Monopar Therapeutics Inc. (Nasdaq: MNPR) is a clinical-stage biopharmaceutical company that develops novel radiopharmaceuticals for oncology and treatments for rare genetic disorders such as Wilson Disease; its pipeline features clinical-stage MNPR-101-Zr, a radiodiagnostic imaging agent for advanced solid tumors expressing urokinase plasminogen activator receptor (uPAR), clinical-stage MNPR-101-Lu and late-preclinical MNPR-101-Ac radiotherapeutic agents conjugated to lutetium-177 and actinium-225 respectively for the same oncology indications, and late-stage ALXN1840 (bis-choline tetrathiomolybdate), an investigational oral therapy that has completed Phase 3 trials for Wilson Disease. The company builds its portfolio through in-house development, licensing of late preclinical and clinical-stage assets, and strategic collaborations, targeting patients with aggressive cancers and rare diseases. Founded in 2014 and headquartered in Wilmette, Illinois, Monopar conducts operations primarily in the United States with its team based in the Chicago area. Recent developments include the October 2024 exclusive worldwide license agreement with Alexion, an AstraZeneca Rare Disease unit, for ALXN1840, which provides access to a Phase 3-completed asset for an upfront payment of $4 million in cash plus Monopar stock; an amendment and expansion in June 2024 of its radiopharmaceutical collaboration with NorthStar Medical Radioisotopes, securing long-term non-exclusive supply of actinium-225, intellectual property rights, and shared patent applications to support MNPR-101-Ac; and activation of two novel Phase 1 clinical trials for MNPR-101-Zr and MNPR-101-Lu enrolling patients with advanced solid cancers.
Company News
Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast
Monopar Appoints Jeffrey D. Kent, M.D.
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Monopar Therapeutics: ALXN1840's Bull Case Has Improved
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025